Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke
|
|
- Patience Kelly
- 5 years ago
- Views:
Transcription
1 Journal of Cerebral Blood Flow & Metabolism (2015) 35, ISCBFM All rights reserved X/15 $ MINI REVIEW Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke Vladimer Darsalia 1, Martin Larsson 1, David Nathanson 1, Thomas Klein 2, Thomas Nyström 1 and Cesare Patrone 1 During the past decades, candidate drugs that have shown neuroprotective efficacy in the preclinical setting have failed in clinical stroke trials. As a result, no treatment for stroke based on neuroprotection is available today. The activation of the glucagon-like peptide 1 receptor (GLP-1) for reducing stroke damage is a relatively novel concept that has shown neuroprotective effects in animal models. In addition, clinical studies are currently ongoing. Herein, we review this emerging research field and discuss the next milestones to be achieved to develop a novel antistroke therapy. Journal of Cerebral Blood Flow & Metabolism (2015) 35, ; doi: /jcbfm ; published online 11 February 2015 Keywords: diabetes; DPP-4 inhibitors; exendin-4; GLP-1; liraglutide; neuroprotection; stroke INTRODUCTION Stroke is the primary cause of severe disability and the second most common cause of death according to the World Health Organization. In all, 85% of all strokes result from any major cerebral artery occlusion leading to cerebral ischemia, brain damage, and consequent neurologic impairments and disability. Recombinant tissue plasminogen activator is the only FDA-approved pharmacological treatment for ischemic stroke. However, this treatment is not available for the majority of stroke patients due to short effective therapeutic window (up to 4.5 hours from stroke symptom onset) and increased risk of cerebral hemorrhage. The ischemic cerebral region can be divided in two subregions: ischemic core and penumbra. The core is the area of infarction where neurons die extremely quickly after a stroke. The surrounding penumbra maintains residual blood flow and neurons could potentially be salvaged by timely intervention. However, if untreated, the penumbra will slowly progress into an infarction. So far, preclinically efficacious neuroprotective drugs targeting the penumbra have failed clinically. 1 The reasons for this failure are multiple and they range from differences in dosage, routes of administration, and timing of drug administration from the onset of stroke. In addition, preclinical efficacy experiments have often been performed in rodent models without typical comorbidities of stroke patients such as diabetes and hypertension, thus not mimicking the likely conditions of stroke patients. Recent research has showed neuroprotective properties against stroke by drugs targeting the glucagon-like peptide-1 receptor (GLP-1R). Some of the stroke efficacy data has been achieved under preclinical conditions of clinical relevance. Furthermore, these substances are already in clinical use for the treatment of type 2 diabetes (T2D) and present a good safety profile and minimal side effects. Therefore, the potential repositioning of GLP-1R activating drugs into antistroke treatments seems promising. THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR Glucagon-like peptide-1 receptor is a G-protein-coupled receptor that is expressed in a wide range of tissues including pancreas, heart, and brain. 2 It is activated by GLP-1; a small peptide hormone released from intestinal L cells and exerting numerous pleiotropic effects. The best-characterized property of GLP-1 is its incretin effect, e.g., enhancing meal-stimulated insulin secretion from pancreatic β cells in a glucose-dependent manner. 2 This effect accounts for the largest part of the postprandial insulin secretion in healthy subjects. Glucagon-like peptide-1 also decreases glucagon secretion from the pancreas. Since these effects are glucose dependent, activation of the GLP-1R carries a low risk of hypoglycemia. The signal transduction pathway of GLP-1 and its analogs has been characterized in pancreatic β cell and it mainly occurs via adenylate cyclase and the camp/pka pathways. 2 Endogenous GLP-1 is rapidly degraded by the enzyme dipeptidyl-peptidase 4 (DPP-4). Thus, despite its glycemic regulatory properties GLP-1 as such could not be developed clinically for the treatment of diabetes. However, there are todays several stable synthetic GLP-1R agonists resistant to DPP-4 degradation and DPP-4 inhibitors that are used clinically to treat T2D. GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIVATION FOR THE TREATMENT OF STROKE In the past few years, neuroprotection via GLP-1R activation has been shown in several animal models of Alzheimer s, Parkinson s, 1 Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden and 2 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. Correspondence: Dr V Darsalia, Dr M Larsson, Dr C Patrone, Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, SE Stockholm, Sweden. vladimer.darsalia@ki.se or martin.larsson@sodersjukhuset.se or cesare.patrone@ki.se Work in our laboratories is supported by the Novo Nordisk foundation, the European Foundation for the Study of Diabetes, Diabetesfonden, the Swedish Heart and Lung Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Diabetes Research & Wellness Foundation and by the foundations Magnus Bergvall, Axel and Signe Lagerman s Donation, Loo and Hans Osterman, Åhlén, STROKE Riksförbundet, Tornspiran, Gamla Tjänarinnor, Syskonen Svensson and by the Fighting Stroke Project (Uppdrag Besegra Stroke) supported by the Swedish Heart and Lung foundation and by the Karolinska Institutet. Received 21 November 2014; revised 13 January 2015; accepted 13 January 2015; published online 11 February 2015
2 Huntington s, and traumatic brain injury. This research field is rapidly growing and several excellent reviews are available (e.g. Holscher 3 ). Herein, we specifically focus on data showing GLP-1R-mediated neuroprotection against stroke. Glucagon-Like Peptide-1 Receptor Agonists Exendin-4. Exendin-4 (Ex-4) is the first GLP-1R agonist that was developed by Amylin Pharmaceuticals (San Diego, CA, USA) as exenatide for the treatment of T2D. It shares a 53% amino-acid sequence homology with GLP-1. The safety profile of Ex-4 is good, although patients can present side effects such as nausea. 2 Besides its metabolic properties, GLP-1Rs are expressed throughout the brain and Li et al 4 showed that intracerebral administration of Ex-4 enhanced neuroprotection and locomotor activity after stroke in the rat. The authors also showed that the effect was mediated by GLP-1R since Ex-4 was ineffective in GLP-1R knockout mice. The work represents proof-of-concept for neuroprotection against stroke by GLP-1R activation. However, the findings have low clinical relevance since Ex-4 was given at stroke onset and via a route of administration not suitable for clinical applications. Exendin-4 can pass the blood brain barrier and data have recently shown that peripheral administration of this compound leads to neuroprotection against stroke. Teramoto et al 5 showed that Ex-4 is neuroprotective and improves neurologic deficit after stroke induced by transient middle cerebral artery occlusion (MCAO) after intravenous injections in mice. 5 Efficacy was achieved when Ex-4 was given acutely at stroke onset or 1 hour later. At 3 hours, the neuroprotective effect was lost. The neuroprotective effect of Ex-4 was independent of glycemic effects and correlated with increased camp levels and decreased oxidative stress and inflammation. This study proved the concept for the efficacy of Ex-4 via peripheral administration. The work has also clinical relevance if the data are interpreted together with a recent work in our group by Darsalia et al 6 showing that Ex-4-mediated neuroprotection could be achieved even if the treatment started 3 hours after MCAO. Although both works could not show the decreased stroke volume when Ex-4 was administered 3 hours after stroke, in the latter study, neuroprotection was detected by stereological counts of surviving neurons in cortex and striatum. The neuroprotective effect correlated with the increase of M2 reparative-microglia markers. This method appears to be more sensitive than stroke volume measurements in 'unmasking' neuroprotection. 6 8 This work also showed that Ex-4 was neuroprotective up to 3 hours after stroke in aged obese/t2d mice. In conclusion, these results suggest that if administered rapidly after stroke Ex-4 could have neuroprotective potential in clinical perspective, in both normal and T2D patients. Type 2 diabetes is a major risk factor for stroke. Furthermore, T2D and stroke are major causes of morbidity and mortality. 9 To simulate the clinical situation of a diabetic patient experiencing a stroke, we showed that 4 weeks intraperitoneal pretreatment with Ex-4 before MCAO followed by another 4 weeks of Ex-4 treatment decreases brain damage in T2D rats. 8 The effect was already significant at the clinically T2D dose (0.1 μg/kg) and occurred independently of the regulation of glycemia. In clinical perspective, the finding has the advantage that T2D patients could receive a therapy based on GLP-1R activation primarily against their diabetes (i.e., antihyperglycemic), while at the same time improving the stroke prognosis. Briyal et al 10 used a similar strategy although the studies were performed in non-diabetic rats. The protective effect of Ex-4 via pretreatment could also be extended to hippocampus by using a cerebral ischemia model targeting the CA1 region in gerbils. 11 As for the studies where Ex-4 was administered after stroke, also in these studies antiinflammatory action by Ex-4 on microglia cells have been shown. In one recent study, Jin et al 12 also showed that hypoxia-inducible factor-1α regulation by Ex-4 may be involved in neuroprotection. 12 Liraglutide. Liraglutide is a stable GLP-1 analog developed by Novonordisk with ~ 97% homology to GLP-1. 2 Similarly to Ex-4, liraglutide is used clinically against T2D, and the side effects are similar as for Ex-4. 2 Interestingly, Sato et al 13 showed that liraglutide administered intraperitoneally 2.5 hours after stroke onset induced neuroprotection in the rat in correlation with VEGF upregulation. 13 As for the works of Teramoto et al and Darsalia et al described above, the data are clinically relevant since efficacy could be achieved in a poststroke setting compatible with the clinical situation. In another recent study, Briyal et al 14 showed that pretreatment with liraglutide in normal and diabetic rats is neuroprotective against stroke in correlation with decreased apoptosis and oxidative stress. These studies could have clinical relevance since the liraglutide chronic regime of administration before stroke could improve stroke prognosis in T2D patients while exerting antidiabetic effects. See Table 1A for a summary of the studies above. Clinical studies with glucagon-like peptide-1 receptor agonists. Retrospective database analysis on 39,275 patients with T2D has showed that exenatide-treated patients had decreased incidence of cardiovascular events, including stroke. 15 A number of clinical trials with GLP-1R agonists are ongoing where the effect on stroke is one of the outcome measures (see Table 1B). While most of these studies are performed in diabetic patients focusing on combined cardiovascular outcome measures, a few of them are directly focusing on stroke patients. Our institution is running a clinical study where patients with suspected stroke are given exenatide en route in the ambulance (see Table 1B #1). Interestingly, a recent clinical feasibility study in 11 stroke patients with diabetes showed that exenatide treatment was safe and did not cause any serious adverse events, but mild nausea. 16 To assess the cardiovascular safety of liraglutide, a phase 3B, multicenter, randomized, double-blinded, placebo-controlled clinical trial with long-term follow-up (LEADER) was initiated in 2010 and it is ongoing 17 (see also Table 1B #6). Dipeptidyl-Peptidase 4 Inhibitors Dipeptidyl-peptidase 4 is a serine aminopeptidase enzyme inactivating the incretins GLP-1 and glucose-dependent insulinotropic polypeptide through a dipeptide cleavage of the penultimate N-terminal amino acid. 2 The DPP-4 inhibition increases incretins short (1 to 2 minutes) half-life and due to this property DPP-4 inhibitors are clinically used to treat T2D. The DPP-4 inhibition also modulates the activity of other factors with potential neuroprotective properties. 18 In contrast to Ex-4 and liraglutide, which are injectable drugs, DPP-4 inhibitors are orally administered. Recent data have shown that intracerebral administration of the DPP-4 inhibitor sitagliptin reduced cortical lesions after MCAO in the rat. 19 Although the work has low clinical relevance due to the employed route of administration, it was the first to show neuroprotection by DPP-4 inhibition. We recently showed that 4 weeks pretreatment with clinical doses of the DPP-4 inhibitor linagliptin (orally) in both normal and T2D/obese mice reduced neuronal loss after MCAO. 7 As expected, the effects of linagliptin correlated with increased plasma GLP-1. However, the neuroprotective effect appeared to be independent of glycemic control. In agreement with this finding, Yang et al 20 showed that 3 weeks treatment with the DPP-4 inhibitor alogliptin before stroke induced by the 3-vessel occlusion technique in normal mice reduced stroke volume. The neuroprotective effect correlated with increased brain derived neurotrophic factor ISCBFM Journal of Cerebral Blood Flow & Metabolism (2015),
3 720 Journal of Cerebral Blood Flow & Metabolism (2015), ISCBFM Table 1A. Bibliometric overviews of preclinical studies and ongoing trials with GLP-1R agonists and DPP-4 inhibitors in stroke (A. Preclinical studies) Author Substance Stroke model Occlusion time (min) Species Administration route No. of animals Comorbidity Main outcome measures a Ref. no. Li, Y Exendin-4 MCAO 60/90 b Rat/Mouse b Iv. 15 minutes before MCAO 14/28 b None SV, BT Lee, CH Exendin-4 Bil carotid 5 Gerbil Ip. 2 hours before surgery and 142 None CC, GLP-1R Western Blot, BT occlusion 1 hour after reperfusion Teramoto, S Exendin-4 MCAO 60 Mouse Iv.. 0, 1 or 3 hours after 81 None SV, BT reperfusion Briyal, S Exendin-4 MCAO Permanent Rat Ip. 7 days before MCAO 30 None SV, BT Darsalia, V Exendin-4 MCAO 90 Rat Ip. 4 weeks before and after 42 Diabetes SV, CC MCAO Darsalia, V Linagliptin MCAO 30 Mouse Oral 4 weeks before and 42 Diabetes, Obese SV, CC 3 weeks after MCAO Sato, K Liraglutide MCAO 90 Rat Ip. 44 None SV, BT Yang, D Alogliptin 3VO 15 Mouse Oral 3 weeks before 3VO 40 None SV, BT Briyal, S Liraglutide MCAO Permanent Rat Sc. 2 weeks before MCAO 30 None SV, BT Darsalia, V Exendin-4 MCAO 30 Mouse Ip. after MCAO 128 Diabetes, Obese, SV, CC, Inflammation old Abbreviations: BT, behavioral/motor tests; CC, cell counting; DPP-4, dipeptidyl-peptidase 4; GLP-1R, glucagon-like peptide-1 receptor; Ip., intraperitoneal; Iv., intravenous; Ivt., intraventricular; MCAO, middle cerebral artery occlusion; Sc., subcutaneous; SV, stroke volume; 3VO, three vessel occlusion. PubMed searched 2015 January 08 for preclinical GLP-1 or DPP-4 studies examining stroke. Articles appear in the order of publication, with Li being the first. a Most studies report multiple outcome measures, here are only the main measures listed. b The study by Li Y has two arms with rat or mouse. First value is mouse, second rat. Table 1B. Bibliometric overviews of preclinical studies and ongoing trials with GLP-1R agonists and DPP-4 inhibitors in stroke (B. Ongoing clinical trials) Substance EU CTR Identifier no. CT.gov Identifier no. Study Planned size Primarily stroke trial # Exenatide (GLP-1R) Prehospital study, hyperglycemic patients with suspected stroke 100 * 1 Exenatide (GLP-1R) Exenatide in patients receiving thrombolytic therapy for stroke 40 * 2 Exenatide (GLP-1R) NCT EXSCEL trial. Diabetics given exenatide as add on, CV events evaluated 14,000 3 Exenatide (GLP-1R) NCT Diabetics, exenatide given with s.c. pump, CV events evaluated 3,000 4 Liraglutide (GLP-1R) Nil by mouth stroke patients. Stroke volume measured by MRI 40 * 5 Liraglutide (GLP-1R) NCT LEADER trial. Diabetics, time to CV event primary outcome. Effect and safety 8,754 6 Saxagliptin (DPP-4) No ongoing studies in both databases 7 Alogliptin (DPP-4) No ongoing studies in both databases 8 Sitagliptin (DPP-4) NCT TECOS trial. Diabetics, time to CV events evaluated 14,757 9 Linagliptin (DPP-4) NCT CARMELINA trial. Diabetics, time to CV events evaluated 10, Linagliptin (DPP-4) NCT CAROLINA trial. Diabetics, time to CV event evaluated 6, Abbreviations: CV, cardiovascular; DPP-4, dipeptidyl-peptidase 4; GLP-1R, glucagon-like peptide-1 receptor; MRI, magnetic resonance imaging. EU Clinical Trial Register (EU CTR) and ClinicalTrials.gov (CT.gov) databases searched with query stroke + substance on 2014 November 8. Each row constitutes a unique study. Retrospective noninterventional studies excluded
4 721 Penumbra Reduced damage Improved recovery Core Direct neuroprotection and Increased stem cell proliferation Increased neurogenesis Increased synaptic plasticity No treatment Increased levels of other DPP-4 substrates Increased GLP-1 levels GLP-1R Agonists DPP-4 inhibitors Neuron Microglia Activated microglia Stem cell Neuroblast New neuron Figure 1. Neuroprotective mechanisms against stroke induced by glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidylpeptidase 4 (DPP-4) inhibitors. GLP-1R agonists and DPP-4 inhibitors could exert neuroprotection via common or independent mechanisms. Evidence is accumulating that direct antiapoptotic survival effects on neurons and indirect effects through the regulation of microglia could be at the basis of acute neuroprotection by GLP-1R agonists. In addition to stimulate neuroprotection by increased plasma GLP-1 levels, DPP-4 inhibitors could also modulate the activity of other neuroprotective factors that will need to be identified. Other potential mechanisms ranging from effects on adult neurogenesis and on synaptic plasticity will need to be investigated to understand whether the effect of both GLP-1R agonists and DPP-4 inhibitors can have a role in late stroke recovery. Although these results are interesting, the responsible mechanisms remain unclear. Unlike GLP-1R agonists, DPP-4 inhibitors do not cross the blood brain barrier. Furthermore, DPP-4 inhibition does not induce an increase in plasma GLP-1 equivalent to pharmacological doses of Ex-4 or liraglutide. Finally, opposite to what has been observed for GLP-1R agonists, antistroke efficacy by alogliptin was lost when the treatment started after stroke onset. 20 We also achieved similar results to those with alogliptin by using linagliptin (unpublished). In conclusion, these data indicate that the biology at the basis of neuroprotection mediated by DPP-4 inhibitors is complex and still largely unexplored. See Table 1A for a summary of the studies above. Clinical studies with dipeptidyl-peptidase 4 inhibitors. A recent meta-analysis study showed lower incidence of cardiovascular diseases (CVD) in diabetic patients receiving DPP-4 inhibitors. 21 A larger 2-year efficacy/safety study comparing linagliptin with glimepiride in T2D patients suggests that linagliptin has a beneficial action on CVD. 22 Recently, a small study including 378 patients showed that DPP4 inhibitors treatment before stroke showed a trend for less severe stroke compared with untreated patients. 23 However, no effect of DPP-4 inhibition on CVD end points, including stroke, was shown in two recently published large cardiovascular outcome trials for saxagliptin 24 and alogliptin. 25 Further, analysis of US commercial insurance including 79,000 patients did not show differences between untreated or DPP-4 inhbitor-treated patients regarding CVD end points including stroke. 26 Table 1B lists ongoing trials with DPP-4 inhibitors. It remains to be shown in the coming trials of TECOS (sitagliptin, see Table 1B #9), CARMELINA (linagliptin, 2015 ISCBFM Journal of Cerebral Blood Flow & Metabolism (2015),
5 722 see Table 1B #10), and CAROLINA (linagliptin, see Table 1B #11) if DPP-4 inhibitors lower stroke incidence and/or improve stroke outcome. In particular, CARMELINA contains a poststroke functional substudy using the modified RANKIN score to assess stroke disability approximately one week after stroke and at ~ 3 months after stoke onset. Of note is that no DPP-4 inhibitor studies are primarily stroke trials. POTENTIAL MECHANISMS AND FUTURE DIRECTIONS During the past few years, experimental evidence has shown that GLP-1R activation is efficacious against stroke in various rodent models. However, the molecular/cellular mechanisms at the basis of GLP-1R-mediated neuroprotection are still largely unknown. Altogether the results point out direct, antiapoptotic and neuroprotective mechanisms and indirect antiinflammatory mechanisms involving microglia regulation (Figure 1). These data are also supported by the fact that GLP-1R has been found on both neurons 27 and microglia. 28 Since neuroprotective efficacy by GLP-1R activation can be achieved both after a chronic pretreatment before stroke and acutely after stroke, it will be important to determine whether the protective mechanisms are the same. Interesting, recent literature by Gejl et al has shown that in response to plasma glucose pathologic alterations, GLP-1 reduces brain glucose levels fluctuation by regulating the brain vasculature. 29 Hyperglycemia worsens the stroke outcome and this mechanism may prove to be neuroprotective during hyperglycemia. Also, it is not known whether neuroprotection mediated by GLP-1R agonists and DPP-4 inhibitors occur through the same mechanism of action and whether neuroprotection by DPP-4 inhibition is indeed GLP-1R dependent. These questions will need to be answered by performing efficacy studies using GLP-1R antagonists and mice lacking the glp-1r. The GLP-1R activation has been reported to increase neurologic recovery and to improve learning and memory in different animal models of neurodegenerative disorders. 3 In addition, GLP-1R activation promotes synaptic plasticity and neurite outgrow 3 and can stimulate adult neurogenesis (Figure 1). 30 The findings could form the bases for potential regenerative therapy for chronic stroke patients. At this regard, experimental data and future work are highly needed. CONCLUSIONS Preclinical efficacy studies and clinical results indicate that an antistroke therapy based on GLP-1R activation might be translated into the clinical practice. A number of these molecules are already in clinical use for the treatment of T2D, making this potential translation easier since these molecules are rather safe. If translation is possible, then the preclinical data indicate that diabetic/high-risk stroke patients receiving GLP-1R therapy before stroke would benefit mostly from this type of treatment. Whether a poststroke acute treatment can lead to neuroprotection in a clinical relevant manner remains to be investigated since the protective effect of GLP-1R agonists in rodents decreases quickly after stroke onset. If so, it would require that the drug administration occurs soon after a stroke event; possibly already during the ambulance transport. Finally, safety/ feasibility studies assessing whether this type of therapeutic strategy is possible will need to be completed and analyzed in the near future. DISCLOSURE/CONFLICT OF INTEREST Work in CP s laboratory is supported by Boehringer Ingelheim Pharma GmbH & Co. TK is an employee of Boehringer Ingelheim Pharma GmbH & Co. TN is on the national advisory board of Eli Lilly, Novonordisk, and Sanofi. REFERENCES 1 Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1: Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014; 221: T31 T41. 4 Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106: Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011; 31: Darsalia V, Hua S, Larsson M, Mallard C, Nathanson D, Nystrom T et al. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial m2 polarization. PLoS ONE 2014; 9: e Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 2013; 62: Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 2012; 122: Sander D, Kearney MT. Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol 2009; 256: Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res 2012; 1427: Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S et al. Ischemia-Induced Changes in Glucagon-Like Peptide-1 Receptor and Neuroprotective Effect of Its Agonist, Exendin-4, in Experimental Transient Cerebral Ischemia. J Neurosci Res 2011; 89: Jin J, Kang HM, Jung J, Jeong JW, Park C. Related expressional change of HIF-1alpha to the neuroprotective activity of exendin-4 in transient global ischemia. Neuroreport 2014; 25: Sato K, Kameda M, Yasuhara T, Agari T, Baba T, Wang F et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci 2013; 14: Briyal S, Shah S, Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience 2014; 281C: Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies a retrospective analysis of the lifelink database. Diab Care 2011; 34: Daly SC, Chemmanam T, Loh PS, Gilligan A, Dear AE, Simpson RW et al. Exenatide in acute ischemic stroke. Int J Stroke 2013; 8: E Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: e5. 18 Omar B, Ahren B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes 2014; 63: Rohnert P, Schmidt W, Emmerlich P, Goihl A, Wrenger S, Bank U et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation 2012; 9: Yang D, Nakajo Y, Iihara K, Kataoka H, Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2,induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res 2013; 1517: Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27 (Suppl 3): Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380: Magkou D, Tziomalos K. Antidiabetic treatment, stroke severity and outcome. World J Diabetes 2014; 5: Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369: White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 2013; 369: Journal of Cerebral Blood Flow & Metabolism (2015), ISCBFM
6 26 Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol 2014; 51: Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20: Gong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci 2014; 34: Gejl M, Egefjord L, Lerche S, Vang K, Bibby BM, Holst JJ et al. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab 2012; 32: Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86: ISCBFM Journal of Cerebral Blood Flow & Metabolism (2015),
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationNeuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationDiscussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationDPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim
DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim Endocrinology of Metabolism, Korea University College of Medicine Conflict of interest disclosure None
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationType 2 diabetes is a strong risk factor for severe. A Comparison With Glimepiride
ORIGINAL ARTICLE The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain A Comparison With Glimepiride Vladimer Darsalia, 1 Henrik Ortsäter, 1 Anna Olverling, 1 Emilia
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDR. SUBHASH K. WANGNOO
Photograph DR. SUBHASH K. WANGNOO M.D, D.M, FRCP (London) Senior Consultant, Endocrinologist & Diabetologist Apollo Centre for Obesity, Diabetes and Endocrinology Indraprastha Apollo Hospital, Sarita Vihar,
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationTargeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes
SHORT COMMENT FOR NATURE REVIEWS ENDOCRINOLOGY Targeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes André J. SCHEEN (1), Nicolas PAQUOT (2) (1)
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationType 2 diabetes and cardiovascular risk: the role of GLP-1
Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India Disclaimer I am an employee of Novo Nordisk
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationNIH Public Access Author Manuscript Diabetologia. Author manuscript; available in PMC 2014 February 01.
NIH Public Access Author Manuscript Published in final edited form as: Diabetologia. 2013 February ; 56(2): 231 233. doi:10.1007/s00125-012-2788-6. Lipotoxicity impairs incretin signalling V. Poitout 1,2
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationInitial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
The journal of interventions in clinical practice www.drugsincontext.com CLINICAL COMMENTARY FULL TEXT ARTICLE Initial combination therapy for patients with type 2 diabetes mellitus: considerations for
More informationUpdate on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American
Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American Association of Diabetes Educators (AADE) for nurses, dietitians,
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationUpdate on GLP-1 Past Present Future
Update on GLP-1 p Past Present Future Effects of GLP-1: Glucose Metabolism and Nutritional Balance L-Cells: Glp-1 release Betacellfollowing ingestion Stress Increases satiety reduces appetite Betacell-
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationSELECTED ABSTRACTS AND POSTER PRESENTATIONS
SELECTED ABSTRACTS AND POSTER PRESENTATIONS The following summaries are based on abstracts and posters presented at the American Diabetes Association s 65th Annual Scientific Sessions held in San Diego,
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationEBAC-Accredited Satellite symposium during ESC 2018, Munich, Germany - August 27, 2018
OUTCOMES OF : WHAT ARE THE KEY OPPORTUNITIES FOR CARDIOLOGY PRACTICE? This EBAC-accredited symposium was held during ESC 2018 in Munich, Germany. Prof. Deanfiel, dr. Knop and prof. Rydén presented evidence
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationCardiovascular Safety of Incretin Based Therapy
Cardiovascular Safety of Incretin Based Therapy John B. Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Executive Associate Dean, Clinical Research University of
More informationTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert
REVIEW Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationDOI: /jemds/2014/2044 ORIGINAL ARTICLE
AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS Mohd. Riyaz 1, Imran 2, Rinu Manuel 3, Nidhisha K. Joseph 4 HOW TO CITE THIS ARTICLE:
More informationDulaglutide (LY ) for the treatment of type 2 diabetes
Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 (LY-2189265) for the treatment of type 2 diabetes André J. Scheen
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More information